DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Claim Objections
Claim 7 is objected to because of the following informalities:
Claim 7, please amend “CFM” to recite “cubic feet per minute (CFM)” in line 2.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 1 recites the term “efficiently” which is a relative term that renders the claim indefinite. The term “efficiently” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. To resolve the issue, please delete the term.
Claim 1 recites the limitation "the biological" in line 10. There is insufficient antecedent basis for this limitation in the claim. It is suggested Applicant amend the limitation to recite “a liquid load of a biological.”
Claim 1 recites the limitation "the liquid biological load" in line 11. There is insufficient antecedent basis for this limitation in the claim.
Claim 1 recites the limitation “a sample collection duct element, each duct element being composed of a pair of opposed walls…” in lines 22-23. It is unclear if the Applicant is referring to the sample collection duct element or the aforementioned “one or more duct elements” in line 21. For examination purposes, the claim will be interpreted as the former. Clarification is requested.
Claims 2-15 are rejected due to their dependence on claim 1 and failure to resolve the issues contained therein.
Claim 8 recites the limitation "the nebulizer" in line 1. There is insufficient antecedent basis for this limitation in the claim. It is suggested Applicant amend the limitation to recite “the nebulization unit.”
Claims 9-15 are rejected due to their dependence on claim 8 and failure to resolve the issues contained therein.
Claim 13, the term “about” is a relative term which renders the claim indefinite. The term “about” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention.
Claim 15, the term “about” is a relative term which renders the claim indefinite. The term “about” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention.
Allowable Subject Matter
Claim 1 contains allowable matter but stands rejected due to the 112 issues discussed above. The Applicant claims an airborne biological assessment threat elimination system for collecting and measuring airborne biologicals and the closest art of record is considered to be Carrieri (US 20220010996 A1).
Regarding claim 1, Carrieri teaches an airborne biological assessment threat elimination system for collecting and measuring airborne biologicals (Fig. 1A, HVAC system 1), the system comprising: an intelligent heating, ventilation, and air conditioning (HVAC) unit for efficiently purifying air of a compartmentalized environment in a manner that deactivates airborne biologicals (Fig. 1A, HVAC unit 10a, [0016], [0103]), the HVAC unit comprising: a nebulization unit [0231], a compressor unit (Fig. 1A, 12, [0230]), a modular ducting subsystem [0146], a first sampling probe [0206-0207], an air purification module [0104], and a second sampling probe [0206-0207].
However, Carrieri does not teach wherein the nebulization unit comprises a plurality of chambers, or that the HVAC unit comprises a fluid pump, as well as a plurality of translation conduits, the plurality of chambers including a biological load chamber and a nebulization chamber, the biological load chamber being coupled to the nebulization chamber by a first translation conduit, and being configured for retaining a liquid load of the biological, the fluid pump for delivering the liquid biological load to the nebulization chamber, wherein the nebulization chamber nebulizes the liquid biological load to produce a nebulized biological load;
wherein the compressor unit coupled to the nebulization unit via a second translation conduit, and being configured for both converting the nebulized biological load into an aerosolized biological load and for delivery via a third translation conduit, wherein the modular ducting subsystem is coupled to the nebulization unit by the third translation conduit, the modular ducting subsystem comprising a first and a second ducting module, each ducting module including at least two segments of one or more duct elements, at least one of the one or more duct elements of each ducting module comprising a sample collection duct element, each duct element being composed of a pair of opposed walls defining a cavity therebetween, the two segments having respective coupling mechanisms that are adapted for removably joining respective duct elements of the two segments together in airtight sealings, the sample collection duct element of the first ducting module being configured for receiving the aerosolized biological load from the nebulization unit via the third translation conduit, and further being configured for directing a first portion of the aerosolized biological load through the first ducting module and into the sample collection duct element of the second ducting module in a manner whereby neither air nor one or more portions of the aerosolized biological load can escape through the airtight sealings, the first sample collection duct element of the second ducting module being configured for receiving a second portion of the aerosolized biological load;
wherein the first sampling probe is coupled to the sample collection duct element of the first ducting module, the first sampling probe having a first elongated reception tube, the first reception tube including a first portion and a second portion, the first portion extending inwards from a first of the opposed walls of the sample collection duct element of the first ducting module, into a cavity defined thereby, and being coupled to a first capture assembly for capturing a first amount of the first portion of the aerosolized biological load so as to produce a first biological load sample, and the second portion of the first reception tube being positioned so as to extend at least partially outside of the first wall, the second portion of the first reception tube being adapted for allowing collection of the first biological load sample;
wherein the air purification module is positioned between the first ducting module and the second ducting module, the air purification module being configured for receiving an uncaptured portion of the aerosolized biological load, for purifying the uncaptured portion of the aerosolized biological load so as to produce the second portion of the aerosolized biological load, and for translating the second portion of the aerosolized biological load into the sample collection duct element of the second ducting module; and
a second sampling probe [0206-0207] coupled to the sample collection duct element of the second ducting module, the second sampling probe having a second elongated reception tube, the second reception tube including a first portion and a second portion, the first portion extending inwards from a first of the opposed walls of the second sample collection duct element into a cavity defined thereby and being coupled to a second capture assembly for capturing a first amount of the second portion of the aerosolized biological load so as to produce a second biological load sample, and the second portion of the second reception tube being positioned so as to extend at least partially outside of the first wall, the second portion for allowing collection of the second biological load sample.
There is no teaching, suggestion, or motivation in the prior art that would make it obvious to one having ordinary skill in the art to modify the system of Carrieri to include the structural limitations as underlined above. Specifically, one having ordinary skill in art would have no motivation to sequentially arrange the nebulization unit, a compressor unit, a modular ducting subsystem, a first sampling probe, air purification module, and a second sampling probe as taught by Carrieri in the manner as recited in the instant claim. Doing so would require a plurality of translation conduits and cavities designed to specifically hold, reduce, and transfer an aerosolized viral load and move it through the HVAC unit in the exact manner as recited by claim 1 which would require hindsight knowledge gleaned from the Applicant’s disclosure.
Claims 2-15 are rejected due to their dependency on claim 1 and the reasons discussed above in section 112.
Conclusion
The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.
US 20160025603 A1 teaches an air flow system for monitoring pathogens within an HVAC system.
US 20190137378 A1 teaches a unit for validate decontamination within an air flow chamber.
US 20240361289 A1 teaches a system for analyzing air of an indoor environment.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nebyate Seged whose telephone number is (703)756-4611. The examiner can normally be reached M-F 8-5:00 pm (EST).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maris Kessel can be reached at (571) 270-7698. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/N.S.S./Examiner, Art Unit 1758
/SEAN E CONLEY/Primary Examiner, Art Unit 1799